Demographic, disease characteristics, and comorbidities of the Latin America countries and the global ASAS-COMOSPA study. All values are %, except for n (%) for categorical or mean (SD) for continuous variables.
| Characteristics | ASAS-COMOSPA | Latin America | Argentina | Colombia | Mexico |
|---|---|---|---|---|---|
| No. patients | 3984 | 390 | 236 | 85 | 69 |
| Male | 65.0 | 63.8 | 61.9 | 60.0 | 75.4 |
| Age, yrs | 44 (14) | 44.6 (14.7) | 45.4 (14.5) | 44.1 (13.9) | 42.6 (16.3) |
| Education level, university | 42.4 | 42.6 | 34.7 | 50.6 | 59.4 |
| Smoking status, current | 23.0 | 16.7 | 22.0 | 10.6 | 5.8 |
| Disease duration, yrs | 8.2 (9.4) | 7.0 (8.1) | 6.7 (8.3) | 5.2 (5.6) | 9.3 (8.7) |
| Disease symptoms | |||||
| Axial involvement | 88.7 | 84.2 | 78.3 | 92.9 | 94.0 |
| Arthritis | 56.4 | 73.9 | 77.0 | 70.6 | 67.2 |
| Enthesitis | 38.0 | 62.5 | 57.9 | 77.6 | 59.7 |
| Dactylitis | 15.6 | 23.8 | 25.5 | 24.7 | 16.4 |
| Uveitis | 20.3 | 15.8 | 14.9 | 11.8 | 23.9 |
| Psoriasis | 22.5 | 23.0 | 33.2 | 4.7 | 10.4 |
| IBD | 5.2 | 3.3 | 3.4 | 3.5 | 3.0 |
| ASDAS-CRP | 2.0 (1.1) | 1.9 (1.1) | 1.8 (1.1) | 2.0 (1.0) | 1.8 (1.4) |
| BASFI | 3.0 (2.7) | 3.4 (2.8) | 3.1 (2.8) | 4.3 (2.2) | 3.7 (3.0) |
| NSAID use, last 3 mos | 67.8 | 71.8 | 71.9 | 68.2 | 76.1 |
| Methotrexate, ever | 32.7 | 47.6 | 48.7 | 42.3 | 50.7 |
| Sulfasalazine, ever | 43.9 | 43.5 | 25.4 | 70.2 | 87 |
| Biological (TNFi), ever | 43.9 | 34.1 | 35.6 | 36.4 | 26.1 |
ASAS-COMOSPA: Assessment of SpondyloArthritis international Society of COMOrbidities in SpA; SpA: spondyloarthritis; IBD: inflammatory bowel disease; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score–C-reactive protein; BASFI: Bath Ankylosing Spondylitis Functional Index; NSAID: nonsteroidal antiinflammatory drug; TNFi: tumor necrosis factor inhibitor.